Efficacy of neoadjuvant chemotherapy in locally advanced colon cancer

The generally accepted strategy for treating locally advanced colon cancer is radical surgery involving resection of the colonic portion with the tumor and lymphadenectomy followed by adjuvant chemotherapy. The issue of increasing the metabolic activity of micrometastases and tumor seeding after removal of the primary tumor remains relevant. Objective. To study the efficacy and safety of neoadjuvant chemotherapy (NACHT) in patients with locally advanced resectable colon cancer. Material and methods. The medical records of 90 patients at the Botkin Hospital from January 1, 2022 to January 1, 2024 with colon adenocarcinoma. with stage cT3 or higher and/or involvement of regional lymph nodes (cN+) regardless of the T value, with the absence of MSI (microsatellite instability), without distant metastasis and with chemotherapy in the XELOX, FOLFOX and FOLFOXIRI regimens were retrospectively analyzed. Results. A full course of NACHT was completed by 83 patients (92.2%) without progression and/or grade III–IV complications. Progression was observed in three patients (3.3%). Surgical treatment was performed in all patients, R0 resections were achieved in 100% of cases. Adjuvant chemotherapy was not received by 29 patients (32.2%). Toxicity during NACHT was observed in 34 cases (37.7%). The incidence of grade III–IV complications was 5 (5.1%). Complete therapeutic pathomorphosis was observed in 3 patients (3.3%), partial tumor response in 39 (43.3%). The median follow-up was 23.1 months, the incidence of progression was 10 months (11.1%). Local relapse was observed in 3 patients (3%), distant metastases — in 7 patients (8%). The 2-year overall and relapse-free survival rates were 94 and 92.8%, respectively. Conclusion. NACNT is safe and effective for patients with colon cancer: tolerability is satisfactory, the risk of progression is minimal, and the incidence of postoperative complications is comparable with the results of the world literature. Prospective comparative studies are needed to further study this topic.

Authors

Institutions

Publication Details

Journal
P A Herzen Journal of Oncology
Published
2025-10-29
DOI
https://doi.org/10.17116/onkolog20251405119
Primary Topic
Colorectal Cancer Surgical Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Efficacy of neoadjuvant chemotherapy in locally advanced colon cancer

Z. A. Bagateliya, Roman Zaytsev, С. С. Лебедев, Д. Н. Греков et al.
P A Herzen Journal of Oncology
Colorectal Cancer Surgical Treatments
article

Efficacy of neoadjuvant chemotherapy in locally advanced colon cancer

Z. A. Bagateliya, Roman Zaytsev, С. С. Лебедев, Д. Н. Греков, Alisa G. Minenkova, К. С. Титов, V. M. Kulushеv, Elizaveta Prokofyeva, A.S. Sharenkova
article en

Abstract

The generally accepted strategy for treating locally advanced colon cancer is radical surgery involving resection of the colonic portion with the tumor and lymphadenectomy followed by adjuvant chemotherapy. The issue of increasing the metabolic activity of micrometastases and tumor seeding after removal of the primary tumor remains relevant. Objective. To study the efficacy and safety of neoadjuvant chemotherapy (NACHT) in patients with locally advanced resectable colon cancer. Material and methods. The medical records of 90 patients at the Botkin Hospital from January 1, 2022 to January 1, 2024 with colon adenocarcinoma. with stage cT3 or higher and/or involvement of regional lymph nodes (cN+) regardless of the T value, with the absence of MSI (microsatellite instability), without distant metastasis and with chemotherapy in the XELOX, FOLFOX and FOLFOXIRI regimens were retrospectively analyzed. Results. A full course of NACHT was completed by 83 patients (92.2%) without progression and/or grade III–IV complications. Progression was observed in three patients (3.3%). Surgical treatment was performed in all patients, R0 resections were achieved in 100% of cases. Adjuvant chemotherapy was not received by 29 patients (32.2%). Toxicity during NACHT was observed in 34 cases (37.7%). The incidence of grade III–IV complications was 5 (5.1%). Complete therapeutic pathomorphosis was observed in 3 patients (3.3%), partial tumor response in 39 (43.3%). The median follow-up was 23.1 months, the incidence of progression was 10 months (11.1%). Local relapse was observed in 3 patients (3%), distant metastases — in 7 patients (8%). The 2-year overall and relapse-free survival rates were 94 and 92.8%, respectively. Conclusion. NACNT is safe and effective for patients with colon cancer: tolerability is satisfactory, the risk of progression is minimal, and the incidence of postoperative complications is comparable with the results of the world literature. Prospective comparative studies are needed to further study this topic.

P A Herzen Journal of OncologyVol. 14(5)
Russian Medical Academy of Continuous Professional Education (RU), Virginia Innovation Partnership Corporation (US)
Openalex Percentile: Top 58%
Colorectal Cancer Surgical Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.